 |
|
|
| |
High Rates of SVR in Patients With HCV Genotype 2 or 3 Infection Treated With Ombitasvir/Paritaprevir/r and Sofosbuvir With or Without Ribavirin
|
| |
| |
Reported by Jules Levin
AASLD Nov 13-17 San Francisco
Stephen Shafran1, David Shaw2, Eric Cohen3, Kosh Agarwal4, Graham R Foster5, Manal Abunimeh3, Bo Fu3, Daniel E Cohen3, Edward Gane6
1University of Alberta Hospital, Edmonton, Alberta, Canada; 2Royal Adelaide Hospital, Adelaide, South Australia, Australia; 3AbbVie Inc., North Chicago, Illinois, United States; 4Institute of Liver Studies, Kings College Hospital, London, United Kingdom; 5Queen Mary University of London, Barts Health, London, United Kingdom; 6Liver Unit, Auckland City Hospital, Auckland, New Zealand
|
| |
|
|
|
|
|
